We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Utah Medical Products IncÂŽ, established in 1978, develops, manufactures and marke...
Utah Medical Products IncÂŽ, established in 197...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Ra PharmaÂŽ is a clinical-stage biopharmaceutical company using a proprietary pept...
Ra PharmaÂŽ is a clinical-stage biopharmaceutic...
We are a pharmaceutical company currently in the preclinical stage, dedicated to d...
We are a pharmaceutical company currently in th...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...
Alexion (NASDAQ: ALXN) is a global biopharmaceu...
Join the National Investor Network and get the latest information with your interests in mind.